ProtAffin AG Granted Patent in USA For Lead Anti-inflammatory Product PA401

14-Sep-2009 - Austria

ProtAffin AG announced that it has been granted a patent by the United States Patent and Trademark Office on anti-inflammatory variants of chemokine IL-8, including the Company’s lead product PA401. PA401 is an IL-8 variant in pre-clinical development at ProtAffin to treat chronic lung inflammation.

Whereas wild-type chemokines are over-expressed in many chronic and acute inflammatory diseases, ProtAffin has developed anti-inflammatory variants of IL-8 with increased affinity for glycan structures found on inflamed endothelium. These anti-inflammatory products do not activate chemokine receptors found on leukocytes.

Dr. Jason Slingsby, CEO of ProtAffin commented: “We are very happy that the US Patent Office has granted us claims protecting our lead anti-inflammatory product PA401, and we were granted a similar patent earlier in 2009 by the European Patent Office. There is an urgent clinical need for biopharmaceuticals which can help patients with chronic lung inflammation in the USA and EU and this patent grant in the USA is an important step in commercialising PA401.”

Other news from the department research and development

Most read news

More news from our other portals

So close that even
molecules turn red...